Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Caleb Gon-Shen Chen"'
Autor:
Ken-Hong Lim, Lo-Ho Chen, Meng-Ta Sung, Ya-Wen Chiang, Jie-Yang Jhuang, Yu-Chen Chang, Caleb Gon-Shen Chen
Publikováno v:
HemaSphere, Vol 7, p e024784f (2023)
Externí odkaz:
https://doaj.org/article/632edb11ced74c0fb126ce9513ac2470
Autor:
Chun-Chia Cheng, Po-Nien Liao, Ai-Sheng Ho, Ken-Hong Lim, Jungshan Chang, Ying-Wen Su, Caleb Gon-Shen Chen, Ya-Wen Chiang, Bi-Ling Yang, Huan-Chau Lin, Yu-Cheng Chang, Chun-Chao Chang, Yi-Fang Chang
Publikováno v:
Journal of Biomedical Science, Vol 25, Iss 1, Pp 1-12 (2018)
Abstract Background Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradi
Externí odkaz:
https://doaj.org/article/6fa8fbb263aa47dc8b21de866be2cfc8
Autor:
Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim
Publikováno v:
International Journal of Gerontology, Vol 7, Iss 1, Pp 40-44 (2013)
Background: Essential thrombocythemia (ET) is classified as a chronic myeloproliferative neoplasm. JAK2 V617F mutation is found in about 50–60% patients with ET. We aim to determine the prevalence of JAK2 V617F mutation and its association with phe
Externí odkaz:
https://doaj.org/article/5f37be7a6b3a4ffc9382b114777bd644
Autor:
Huan-Chau Lin, Shu-Ching Wang, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Nai-Wen Su, Hung-I Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Chien-Chung Chang, Yuchi Hwang, Ken-Hong Lim, Yuan-Yeh Kuo
Publikováno v:
International Journal of Gerontology, Vol 7, Iss 3, Pp 186-188 (2013)
In addition to the JAK2 V617F mutation, somatic mutation in DNMT3A has been described in BCL-ABL1-negative myeloproliferative neoplasms (MPNs). We have screened for DNMT3A exon 23 mutations in 130 adult Taiwanese patients with chronic phase myeloprol
Externí odkaz:
https://doaj.org/article/8da35d0012b24a9892ca26cdea777184
Publikováno v:
International Journal of Gerontology; Oct2023, Vol. 17 Issue 4, p247-253, 7p
Autor:
Jo-Ning Wu, Johnson Lin, Yu-Cheng Chang, Caleb Gon-Shen Chen, Ying-Wen Su, Jie-Yang Jhuang, Yi-Fang Chang, Ken-Hong Lim, To-Yu Huang, Yi-Hao Chiang, Huan-Chau Lin
Publikováno v:
Blood Adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b761f82f8579545f98e365c6f490b3cb
https://doi.org/10.1182/bloodadvances.2020003980
https://doi.org/10.1182/bloodadvances.2020003980
Autor:
Caleb Gon-Shen Chen, Ming-Chih Chang, Yi-Fang Chang, Chia-Ching Chang, Ken-Hong Lim, Kate Hsu, Chia-Yu Chang, Lih-Chyang Chen, Chen-Wei Kao
Publikováno v:
Cell Death and Disease, Vol 11, Iss 9, Pp 1-13 (2020)
Cell Death & Disease
Cell Death & Disease
BAFF supports B-cell survival and homeostasis by activating the NF-κB pathway. While NF-κB is also involved in the priming signal of NLRP3 inflammasome, the role of BAFF in NLRP3 inflammasome regulation is unknown. Here we report BAFF engagement to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::383b676348444d2fe8bec54b38bf131f
http://link.springer.com/article/10.1038/s41419-020-03035-2
http://link.springer.com/article/10.1038/s41419-020-03035-2
Autor:
Yi-Fang Chang, Yen-Ning Hsu, Hung-I Cheng, Yu-Cheng Chang, Chih-Kuang Chuang, Chen-Wei Kao, Caleb Gon-Shen Chen, Kate Hsu, Ken-Hong Lim, Yi-Hao Chiang, Ming-Chih Chang
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-10 (2021)
Blood Cancer Journal, Vol 11, Iss 11, Pp 1-10 (2021)
Tyrosine kinase inhibitors (TKIs) that target BCR-ABL are the frontline treatments in chronic myeloid leukemia (CML). Growing evidence has shown that TKIs also enhance immunity. Since gamma-delta T (γδT) cells possess the potent anticancer capabili
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::238e05936ebaa6a592bd8584624b79b5
https://doi.org/10.1038/s41408-021-00572-7
https://doi.org/10.1038/s41408-021-00572-7
Autor:
Ai Sheng Ho, Yu-Cheng Chang, Ya Wen Chiang, Bi Ling Yang, Chun Chao Chang, Po Nien Liao, Yi Fang Chang, Ken-Hong Lim, Jungshan Chang, Ying Wen Su, Caleb Gon-Shen Chen, Huan Chau Lin, Chun Chia Cheng
Publikováno v:
Journal of Biomedical Science, Vol 25, Iss 1, Pp 1-12 (2018)
Journal of Biomedical Science
Journal of Biomedical Science
Background Cancer stem cells are capable of undergoing cell division after surviving cancer therapies, leading to tumor progression and recurrence. Inhibitory agents against cancer stem cells may be therapeutically used for efficiently eradicating tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2172eaa308aa5c17123f6497d354568
http://link.springer.com/article/10.1186/s12929-018-0456-y
http://link.springer.com/article/10.1186/s12929-018-0456-y
Autor:
Jungshan Chang, Kuei Fang Chou, Cheng Liang Peng, Nai Wen Su, Ying Wen Su, Chun Chia Cheng, Ken-Hong Lim, Cheng-Wen Wu, Yi Fang Chang, Ai Sheng Ho, Yu-Cheng Chang, Huan Chau Lin, Caleb Gon-Shen Chen, Bi Ling Yang, Ya Wen Chiang
Publikováno v:
Lung Cancer. 116:80-89
Objectives YM155, an inhibitor of interleukin enhancer-binding factor 3 (ILF3), significantly suppresses cancer stemness property, implying that ILF3 contributes to cell survival of cancer stem cells. However, the molecular function of ILF3 inhibitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ab4495383377befc0eab6ac180c9dc
https://doi.org/10.1016/j.lungcan.2017.12.017
https://doi.org/10.1016/j.lungcan.2017.12.017